
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.

Published: January 18th 2014 | Updated:

Published: February 11th 2014 | Updated:

Published: November 27th 2013 | Updated:

Published: October 4th 2014 | Updated:

Published: March 12th 2014 | Updated: